title: Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.
abstract: Eravacycline demonstrated in vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with MIC50/MIC90 values, respectively, for Escherichia coli of 0.12/0.5 μg/ml, Klebsiella pneumoniae of 0.25/1 μg/ml, Enterobacter aerogenes of 0.25/1 μg/ml, Enterobacter cloacae 0.5/1 μg/ml, and Acinetobacter baumannii of 0.5/1 μg/ml. Activity was retained against multidrug-resistant isolates, including those expressing KPC and OXA carbapenemases. For A. baumannii, eravacycline MICs correlated with increased expression of the adeB gene.
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: Marie
authors.initials: M
authors.lastname: Abdallah
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: Olawole
authors.initials: O
authors.lastname: Olafisoye
authors.affiliation: The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Cortes
authors.affiliation: The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
authors.forename: Carl
authors.initials: C
authors.lastname: Urban
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
authors.forename: David
authors.initials: D
authors.lastname: Landman
authors.affiliation: Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA jquale@downstate.edu.
authors.forename: John
authors.initials: J
authors.lastname: Quale
mesh_terms: D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D006761:Hospitals; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D009519:New York City; D013754:Tetracyclines / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D013754:Tetracyclines; C571179:eravacycline